Mylan Inc.: PharmaVitae Profile now available at ReportsandReports

Dallas, TX: ReportsandReports announce Mylan Inc.: PharmaVitae Profile Market Research Report in its Store. Browse complete Report at: http://www.reportsandreports.com/reports/9244-mylan-inc-pharmavitae-profile.html This analysis examines the historical and forecast performance for Mylan in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information. Reasons to Purchase • Benchmark Mylan's performance against key rivals in the prescription pharmaceutical sector • Assess how the acquisition of Merck KGaA's generics division will impact Mylan's forecast performance • Consider Mylan's strategy to maintain its position as the world's third largest generics company • Table Of Contents • ABOUT DATAMONITOR HEALTHCARE 2 • About the PharmaVitae team 2 • Chapter 1 About this profile 3 • PharmaVitae Explorer database 3 Chapter structure 3 Executive summary 3 Quarterly news update 3 Company introduction 3 Company sales 4 Company financials 4 Key products and competitors 4 Data sourcing 4 Sales data 4 Analyst consensus 4 • Chapter 2 Executive summary 5 • Key findings 5 Prescription pharmaceutical sales and growth rate performance, 2002-14 6 Financial performance, 2002-14 7 Mylan: PharmaVitae forecasts at a glance 8 Strategic insight 9 1) 2002-06: Modest growth amid increasing US competition 10 2) 2007-09: M&A sustains position as third largest generics player 10 3) 2010-14: Profit growth via synergies and geographic expansion 11 SWOT analysis 13 Strengths 13 Weaknesses 14 Opportunities 14 Threats 14 • Table of Contents 16 • Table of figures 18 • Chapter 3 Quarterly news update 19 • Product developments 19 Deals and alliances 20 Product deals 20 M&A activity 21 Company announcements 22 • Chapter 4 Company introduction 24 • Key findings 24 Background 25 Key corporate developments 25 M&A history 25 Early M&A boosts branded Prescription pharmaceuticals capacity 26 Matrix acquisition provides API capabilities 26 Acquisition of Merck Generics 27 Mylan/Merck combination becomes third largest global generics player 27 The acquisition expands Mylan's geographical presence 27 Acquisition of Merck KGaA's CEE generics business 28 Mylan- potential for further M&A? 28 Current corporate structure 29 Generics Segment 29 Specialty Segment 29 Matrix Segment 30 • Chapter 5 Company sales 31 • Key findings 31 Prescription pharmaceutical sales and growth rate analysis, 2002-14 32 Product analysis 34 Product analysis, 2002-08 34 Product analysis, 2008-14 38 Therapy area analysis 42 Geographic analysis 45 Launch portfolio analysis 48 Launch analysis, 2008-14 48 Molecule type analysis 50 Externalization analysis 53 • Chapter 6 Company financials 56 • Key findings 56 Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2002-08 57 Operating costs and profit analysis 58 Operating costs and profit analysis, 2002-08 59 Operating cost ratio and profit margin analysis, 2002-08 60 Operating cost ratio and profit margin analysis, 2008-14 61 Operating costs and profit analysis, 2008-14 63 • Chapter 7 Key products and competitors 64 • Overview 64 Central nervous system 65 EpiPen 65 Overview 65 Sales forecast 66 EpiPen sourced through Dey LP acquisition 66 Revenues affected by seasonal factors 66 Competition from Sciele's TwinJect 66 Next generation device launched in October 2009 67 Respiratory 68 Perforomist 68 Overview 68 Sales forecast 69 Perforomist offers advantages over DuoNeb 69 Competition expected from Sepracor's Brovana 69 DuoNeb 70 Overview 70 Sales forecast 71 DuoNeb to face declining sales over 2008-14 71 Oncology 72 gen. Xeloda 72 Mylan is forecast to launch a generic version of Roche's Xeloda (capecitabine) in 2013. This launch date is based upon the patent expiry of the branded colon and breast cancer drug, however, should Mylan successfully challenge this patent protection, Mylan could launch gen. Xeloda at an earlier date. Mylan believes it is the first company to have filed a substantially complete ANDA containing a Paragraph IV certification for Xeloda and expects to qualify for 180 days of sole marketing exclusivity once final FDA approval is obtained. Roche filed a lawsuit on April 8 2009 alleging Mylan's infringement of US patent no. 5,472,949. 72 Overview 72 Sales forecast 73 gen. Copaxone 74 Overview 74 Sales forecast 75 gen. Copaxone is product of Mylan's alliance with NATCO Pharma 75 Manufacturing complexity will prove an obstacle 75 Sandoz/Momenta offering expected to be first generic to US market 76 gen. fentanyl 77 Overview 77 Sales forecast 78 Mylan owns the majority of the fentanyl patch market 78 Teva enters the Duragesic market in Q3 2008 78 Recall in 2008 expected to have a lasting impact on generic sales 78 gen. Depakote ER 80 Overview 80 Sales forecast 81 Depakote ER generic launched in 2009 81 Sales to decline post-2009 81 • Chapter 8 Appendix 82 • References 82 Abbreviations 82 Exchange rates 83 About Datamonitor 84 About Datamonitor Healthcare 84 Datamonitor consulting 84 Disclaimer 86 ABBREVIATIONS Browse all : Healthcare Market Research Reports http://www.reportsandreports.com/cat/healthcare-market-research.html Browse all : Datamonitor Market Research Reports http://www.reportsandreports.com/Publisher/datamonitor-market-research.html-market-research.html Browse all Newly Published Market Research Reports http://www.reportsandreports.com/LatestReport.aspx Original Source : PharmaV itae Market http://www.reportsandreports.com/reports/9244-mylan-inc-pharmavitae-profile.html Buy Now : Market Research Report http://www.reportsandreports.com/ Related Reports: Browse all : Mylan, Inc.-Detailed Product Pipeline at : http://www.reportsandreports.com/reports/3925-mylan-inc-detailed-product-pipeline.html Browse all : Mylan, Inc.-Deals & Alliances Report at : http://www.reportsandreports.com/reports/4376-mylan-inc-deals-alliances-report.html Browse all : Mylan, Inc.-Therapeutic Competitors at : http://www.reportsandreports.com/reports/3491-mylan-inc-therapeutic-competitors.html Browse all : Mylan Inc. - SWOT Analysis at : http://www.reportsandreports.com/reports/1970-mylan-inc-swot-analysis.html Browse all : Forest Laboratories Inc.: PharmaVitae Profile at: http://www.reportsandreports.com/reports/16328-forest-laboratories-inc- pharmavitae- profile.html About Us: Reports and Reports comprises an online library of 10,000 reports, in-depth market research studies of over 5000 micro markets, and 25 industry specific websites. Our client list boasts almost all well-known publishers of such reports across the globe. We as a third-party reseller of market research reports employ a number of marketing tools, such as press releases, email-marketing and effective search-engine optimization techniques to drive revenues for our clients. We also provide 24/7 online and offline support service to our customers. Contact: Ms. Sunita 7557 Rambler road, Suite 727, Dallas, TX 75231 Tel: +1-888-989-8004 Website: http://www.reportsandreports.com/ Blog: http://reportsnreports.wordpress.com/ Blog: http://reportsandreports.blogspot.com/

Mylan Inc.: PharmaVitae Profile now available at ReportsandReports

About The Author

Law Admin

Subscibe to LawFuel

About The Author

Law Admin

Read More